Debu Tripathy

Dr. Debu Tripathy, editor-in-chief of CURE magazine, discusses the advancements made in small cell lung cancer.

MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.

Activating mutations in this class of oncogenes, specifically KRAS, have made a big step forward scientifically and clinically just in the last couple of years.

Many things can influence a patient’s response to the COVID-19 vaccine, such as their treatments or whether they have a higher tumor burden.

The past year has spotlighted racial inequities not only in the U.S., but worldwide. It has also opened our eyes as to how a major health disruption — in this case, a pandemic — can aggravate the unacceptable status quo.

In this issue of CURE magazine, we review the current approaches for the evaluation and treatment of metastatic breast cancer, and what the future holds.

Receiving a cancer diagnosis is a turning point, a moment at which patients need to start determining what seems like the right treatment path and exerting their best efforts to make it happen.

Immunotherapy – it's the buzzword of the moment. It would be difficult to imagine an area of the field generating more excitement and hope than immuno-oncology is sparking right now.

Medical and scientific communities continue to weigh the value of PSA screening

Throughout the history of medicine, there has been an intriguing interplay between pop culture and science.

Understanding how the immune system controls itself has led to advances in immunotherapy.

Debu Tripathy, editor-in-chief of CURE and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses adding the targeted drug Ibrance to the hormonal drug Faslodex.